CN110876740B - Use of volvalerenal K for repairing skin lesions - Google Patents
Use of volvalerenal K for repairing skin lesions Download PDFInfo
- Publication number
- CN110876740B CN110876740B CN201910782834.5A CN201910782834A CN110876740B CN 110876740 B CN110876740 B CN 110876740B CN 201910782834 A CN201910782834 A CN 201910782834A CN 110876740 B CN110876740 B CN 110876740B
- Authority
- CN
- China
- Prior art keywords
- skin
- ointment
- wound
- volvalerenal
- scald
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Abstract
The invention discloses a new application of a cabernet alkane sesquiterpene volvalenal K in repairing damaged skin, belonging to the field of medicines. The composition can be made into topical medicine, and has remarkable therapeutic effect on skin laceration caused by puncture, scratch, scald or anal fissure.
Description
Technical Field
The invention relates to a new application of an effective component volvalenal K extracted from a traditional Chinese medicine in the medical field, belonging to the field of medicines.
Background
The volvalerenal K (1-hydroxy-1,11,11-decahydrocyclopropane azulene-10-one) is a white crystal of norbonesene sesquiterpene from dried rhizome of Valeriana officinalis Latifolia, and its molecular formula is C 14 H 22 O 2 (m/z 245.1511[M+Na] + ,calcd for C 14 H 22 O 2 Na, 245.1517) and the structure is shown in the attached drawing of the specification.
The research on volvalerena K in the field is relatively few, and the inventor firstly extracted and separated volvalerena K from valerian latifolia (national institute of military medical science and liberals, promiscuous of people, 2014, a doctor academic paper of anti-H5N 1 virus active ingredients research of valerian latifolia, and a revised compound 33 is named as volvalena K), and found that the volvalena K can improve the learning and memory capacity of Alzheimer disease model mice by regulating cholinergic nervous system related enzymes (China New medicine, volume 25, phase 13 in 2016, and improvement of learning and memory capacity of APP double-transgenic dementia mice by volvalerena K in valerian (A latifolia).
The inventors continued research on volvalerena K.
Disclosure of Invention
The invention aims to provide a new medical application of volvalerena K, in particular to a new application of the component in repairing damaged skin.
Furthermore, the medicine containing the volvalena K as the active ingredient can be used for treating symptoms such as cracks on the surface of the skin, bleeding and the like, including cracks caused by stabbing wounds, scratching wounds, scalding, various anal fissures and the like, wherein the cracks include but are not limited to the skin. Of course, in actual application, the volvalerena K can also be prepared into the form of pharmaceutically acceptable salts and prepared into various dosage forms according to the treatment needs, especially external preparations.
Description of the drawings:
FIG. 1: structural drawing of volvalerenal K molecule
Detailed Description
From 2011, Guananmen hospital of Chinese academy of traditional Chinese medicine, a series of researches are carried out on the medicinal application of valeriana latifolia and the contained components, and the following experimental conditions are the drug effect verification of the volvalena K component, so that the effect of the volvalena K in repairing damaged skin is proved.
The first embodiment is as follows: therapeutic effect of the ointment on skin wound
100 patients scratched by a sharp instrument in the period of 8 months in 2017 to 8 months in 2018 of Guangan door hospital, China academy of science and technology are selected as research objects and are randomly divided into a control group and a treatment group, wherein 50 patients are respectively selected, and the average age and the general data of the two groups of patients are compared without significant difference (P & gt 0.05).
Inclusion criteria were: the length of the wound is within the range of 0.5-3 cm, and the width is within the range of 0.2 mm; slight or no bleeding from the wound; the patients gave informed consent.
Experimental drugs: yunnan white drug powder, produced by Yunnan white drug powder group GmbH;
healing ointment: the self-made ointment is prepared by adding the volvalena K into an ointment matrix, and the content of the volvalena K is 20 mg/g.
The experimental method comprises the following steps: the control group is treated with Yunnan white drug powder, the patients in the treatment group are dipped in the guaiacum and smeared uniformly, and the healing effect is observed after 5 days.
Evaluation criteria: the wound is completely healed, the wound becomes effective, and the wound is ineffective without obvious change.
TABLE 1 comparative table of healing effect of wound
The clinical experiment results show that the ointment for treating the skin fracture can obviously promote the healing of the skin wound, and the effect is better than that of a control group.
Example two: the ointment has therapeutic effect on scald
50 patients with mild burn and scald from 2018 to 2019 in Guangan Men hospital, 28 men and 22 women, of Chinese academy of science and science are selected; age 12-68 years; 26 cases of superficial first degree burn and 24 cases of second degree burn have the largest wound area of 8 percent and the smallest wound area of 1 percent.
Inclusion criteria were: superficial burn and scald; the area of burn and scald is less than 10%; within 12h of injury; the scald parts are mostly positioned on the upper limbs, the upper abdomen and the middle lower part of the lower leg 1/3; shock symptoms are not evident.
Experimental drugs: yushui ointment (same as the first embodiment)
The treatment method comprises the following steps: the ointment is dipped in cotton swab and smeared on the wound surface of the burn and scald evenly, and the treatment effect is observed after 7 days.
Evaluation criteria:
and (3) curing: the new epithelium on the wound surface is covered completely, and the wound surface is dry and clean without exudation, pain and infection. The method has the following advantages: the wound surface is covered with new epithelium, and is dry and tidy, red and swollen, slightly painful, and free of exudation and infection. And (4) invalidation: the wound surface is red and swollen, and has more effusion and infection.
TABLE 2 therapeutic effect on burn and scald
The 7-day clinical result shows that the ointment for healing fissures can effectively treat burns and scalds, and the total effective rate is over 95 percent.
Example three: the ointment has therapeutic effect on anorectal diseases such as anal fissure
100 patients diagnosed with anal fissure in Guangan hospital, Guangan academy of Chinese science, 2018-2019, are selected, and are randomly divided into a control group and a treatment group, wherein each group comprises 50 patients. Wherein the age of the control group is 3-75 years, and the average age is 42.37 years in 26 men and 24 women; the treatment groups comprise 23 men and 27 women, the ages of the two groups are 2-78 years, and the average age is 40.21 years. The average age of two groups of patients and the general data are compared, and no significant difference exists (P > 0.05).
Inclusion criteria were: various types of anal fissure; the wound is not healed for more than 1 week.
Experimental drugs: mayinglong pile ointment, Mayinglong medical group company Limited, the product Yushui ointment (same as the first embodiment)
The experimental method comprises the following steps: the control group adopts Malilong musk hemorrhoid ointment as control; the patients in the treatment group cleaned anus with clear water after each defecation, wiped to dryness, dipped in the guaiacum with a cotton swab, uniformly smeared inside and outside the anus, wiped to dryness after half an hour, 5 days is 1 treatment course, and clinical efficacy is observed after 10 days.
Evaluation criteria: the wound is completely healed and becomes effective, and the wound is not obviously changed and becomes ineffective.
TABLE 3 therapeutic effect comparison table
Clinical tests show that the curative effect of the ointment for treating anal fissure is obviously better than that of the Mayilong musk ointment for treating anal fissure (60.10%), the total effective rate is 94.13%, and the curative effect is improved by 34.03% compared with that of the Mayilong musk ointment for treating the anal fissure.
Claims (3)
1. Use of the norcabergoline sesquiterpene volvalenalk in the preparation of a topical medicament for the repair of damaged skin.
2. Use according to claim 1, characterized in that said broken skin is a bleeding symptom of a breach in the skin surface, or is associated with a bleeding symptom.
3. Use according to claim 1, characterized in that the broken skin is a laceration caused by a puncture, a scratch, a scald or an anal fissure.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910782834.5A CN110876740B (en) | 2019-08-22 | 2019-08-22 | Use of volvalerenal K for repairing skin lesions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910782834.5A CN110876740B (en) | 2019-08-22 | 2019-08-22 | Use of volvalerenal K for repairing skin lesions |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110876740A CN110876740A (en) | 2020-03-13 |
CN110876740B true CN110876740B (en) | 2022-08-16 |
Family
ID=69727493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910782834.5A Active CN110876740B (en) | 2019-08-22 | 2019-08-22 | Use of volvalerenal K for repairing skin lesions |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110876740B (en) |
-
2019
- 2019-08-22 CN CN201910782834.5A patent/CN110876740B/en active Active
Non-Patent Citations (2)
Title |
---|
AChE在小鼠皮肤切创愈合过程中的时序性表达及分布;赵建新等;《法医学杂志》;20190430;第35卷(第2期);143-148页 * |
宽叶缬草中volvalerenal K对APP 双转基因痴呆小鼠学习记忆的改善;陈恒文等;《中国新药杂志》;20160731;第25卷(第13期);1466-1470页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110876740A (en) | 2020-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105797204A (en) | Application of chlorogenic acid in preparing wound dressing | |
CN103705616A (en) | Formula of paste for removing slough and promoting growth of tissue regeneration | |
US4469702A (en) | Analgesic composition and use thereof to ameliorate deep and intractable pain | |
CN103656092A (en) | Ointment for treating trauma and preparation method thereof | |
CN110876740B (en) | Use of volvalerenal K for repairing skin lesions | |
CN104474536A (en) | Fresh agrimonia pilosa medicine preparation for treating wounds | |
Salmah et al. | Synergistic effects of alcoholic extract of sweet basil (Ocimum basilicum L.) leaves and honey on cutaneous wound healing in rats | |
WO2018161890A1 (en) | Application of berberine in preparing drug for treating acute soft tissue injury | |
CN109731040A (en) | A kind of wound remediation composition, preparation method and applications | |
CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
ES2377612A1 (en) | Use of crassula for treating proliferative diseases | |
Al-lethie et al. | Evaluation of clinical recovery and healing of oral lesions by 3 different therapeutic regimens in cattle with foot and mouth disease (FMD) | |
CN106728069B (en) | Slough-removing and tissue regeneration-promoting paste for treating scalds and burns | |
CN105832817B (en) | Application of pyrroloquinoline quinine to pharmaceutical compositions for treatment of burns, scalds and traumas | |
CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
CN115040501B (en) | Application of cis-13-octadecenoic acid or salt compound thereof in preparation of drugs for promoting healing of damaged skin and/or mucous membrane | |
CN110538244B (en) | Traditional Chinese medicine composition for promoting skin wound healing | |
CN1303682A (en) | Preparation method of medicine for curing surgical diseases of traditional Chinese medicine | |
CN108245506B (en) | Application of arctigenin in preparation of medicine for treating corneal ulcer | |
CN1275616C (en) | Compsn. of medication for treating burns and scalds | |
CN109260297B (en) | A Chinese medicinal composition for treating hemorrhoid, and its preparation method | |
CN107519178A (en) | Therapeutic action of the 11 carbonyl β acetyl boswellic acids (AKBA) to peripheral nerve injury | |
CN1304028C (en) | Medicinal powder for treating burn and scald | |
RU2589257C1 (en) | Zverkalipt | |
CN106138143A (en) | Pure Chinese medicine burn and scald, bedsore treatment liquid and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |